Do GLP-1 Drugs Work for Everyone? How Genetics May Affect Weight Loss Results

_{Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last}

Medicines such as Ozempic and Wegovy have changed the treatment of type 2 diabetes and obesity.

Many people achieve significant weight loss with GLP-1 medicines.

But the results are not identical for everyone.

Some people lose more weight than others. Some experience stronger side effects. Others see less improvement in blood sugar or weight than expected.

New research in 2026 suggests that genetics may be one factor behind these differences.

But there is an important point to understand.

The research does not prove that exactly 10% of people will fail to lose weight because of genetics. The strongest current evidence shows that certain genetic variants can affect GLP-1 sensitivity and treatment response, particularly blood-sugar control, while other research has identified genetic differences associated with weight-loss effectiveness.

What Are GLP-1 Drugs?

GLP-1 stands for glucagon-like peptide-1.

It is a natural hormone that helps regulate:

Blood sugar
Insulin release
Appetite
Digestion
Feelings of fullness

GLP-1 receptor agonists imitate some of these effects.

Semaglutide is used in Ozempic and Wegovy.

These medicines can reduce appetite, slow stomach emptying and help people consume fewer calories.

Tirzepatide, used in Mounjaro and Zepbound, works on both GIP and GLP-1 pathways.

The Genetics Factor

Researchers are becoming increasingly interested in the possibility that genetic differences can affect how the body responds to GLP-1 medicines.

One 2026 study published in Genome Medicine examined variants in the PAM gene.

The gene produces an enzyme involved in activating several biologically important hormones, including GLP-1.

Researchers found that certain genetic variants could reduce biological sensitivity to GLP-1 signaling.

In simple terms, someone could have higher levels of GLP-1 but still have a weaker response to its effects.

Does This Mean Some People Are “GLP-1 Resistant”?

The term is being used in research, but it needs to be handled carefully.

The study provides evidence that certain genetic variants can reduce GLP-1-related biological response.

It does not mean that everyone carrying one of these variants will fail to lose weight with a GLP-1 medicine.

The evidence is strongest for differences in glucose-lowering response.

The effect on obesity-related weight loss is still being studied.

What About Weight Loss Specifically?

A separate 2026 genome-wide study looked directly at genetic predictors of GLP-1 receptor agonist weight loss.

Researchers identified a missense variant in the GLP1R gene that was significantly associated with greater weight-loss effectiveness.

The estimated difference was about 0.76 kg of additional weight loss per copy of the effect allele.

The study also identified genetic associations with side effects such as nausea and vomiting.

This is important because it provides direct evidence that genetics can contribute to variation in response.

But the effect of an individual genetic variant is only one piece of a much larger picture.

Genetics Is Not the Only Reason GLP-1 Drugs May Work Less Well

Someone who loses less weight than expected should not automatically assume that genetics is responsible.

Other factors can include:

Dose
Missed doses
Treatment duration
Side effects
Treatment interruptions
Diet
Physical activity
Sleep
Stress
Other medicines
Existing medical conditions
Metabolic health

The original article correctly highlighted several of these factors.

What If a GLP-1 Drug Does Not Work Well?

There are still options.

A doctor may first review whether the patient has:

Taken the medicine consistently
Reached an appropriate dose
Used it for enough time
Experienced side effects that limited treatment
Made appropriate dietary and activity changes
Developed another medical issue affecting progress

A healthcare professional may then consider whether another approved medicine or treatment strategy would be more appropriate.

The expanding range of treatments makes this increasingly important.

Our article on new oral weight-loss and diabetes drugs looks at oral GLP-1 medicines and experimental approaches designed to improve metabolism and preserve muscle.

Could Genetics Help Doctors Choose the Right Drug?

That is one of the biggest possibilities.

Imagine a future in which a doctor could combine:

Genetic information
Metabolic health
Body composition
Previous treatment response
Side-effect risk
Medical history
Lifestyle factors

The result could be a more personalized treatment plan.

But routine genetic testing for choosing a GLP-1 medicine is not yet standard obesity care.

More research is required before genetic testing can reliably guide everyday prescribing decisions.

What About Muscle Loss?

Another important issue is the quality of weight loss.

Losing body weight is not the only goal.

Preserving muscle is also important for:

Strength
Mobility
Glucose metabolism
Physical independence
Long-term health

That is why researchers are studying treatments that may work alongside GLP-1 medicines.

Our article on new oral weight-loss drugs and muscle-targeted treatments discusses ATR-258, an experimental approach designed to target skeletal muscle metabolism.

What About Other Effects of GLP-1 Medicines?

The research into GLP-1 medicines is no longer limited to diabetes and obesity.

Scientists are also studying their possible effects on reward-related behaviors.

For example, a 2026 randomized trial found that oral semaglutide reduced several alcohol-related outcomes among people with moderate to severe Alcohol Use Disorder.

Our article on GLP-1 drugs and alcohol cravings examines that research separately.

The Larger Weight-Loss Drug Revolution

The growing evidence about genetics comes at the same time as the obesity-treatment market is expanding rapidly.

New oral medicines, next-generation GLP-1 drugs, combination treatments and experimental therapies are all being studied.

Our SlimFitAffiliate ‘Pillar Article’ on new weight-loss drugs and obesity treatment brings these developments together in one place.

The Future May Be Personalized

The important question may eventually change.

Instead of asking:

“Do GLP-1 drugs work?”

we may ask:

“Which GLP-1 or other obesity treatment is most likely to work for this particular person?”

That is the direction in which precision medicine is moving.

Genetics may become one part of the answer.

But genetics will probably be combined with many other factors rather than used alone.

Final Thoughts

GLP-1 medicines such as Ozempic and Wegovy are powerful treatments, but they are not a one-size-fits-all solution.

Genetic research is beginning to explain why some people may respond differently.

The 2026 studies provide evidence that genetic variation can influence GLP-1 sensitivity, weight-loss effectiveness and some side effects.

But genetics is only one piece of the puzzle.

A less-than-expected response does not automatically mean that someone is genetically resistant.

The right approach is to review the complete clinical picture with a qualified healthcare professional.

The future of obesity treatment may not be about finding one medicine that works best for everyone.

It may be about finding the right treatment for the right person.

Medical Disclaimer

This article is for educational and informational purposes only. It is not medical advice, diagnosis or treatment. Do not start, stop or change prescription medication without consulting a qualified healthcare professional.

References

Written by Ravi Tiku

Publisher & Author | 38 Years of Pharmaceutical Sales Experience

[Medical information note: This article is for general educational purposes and is not a substitute for professional medical advice.]